Skip to main content

Table 2 Management of IPF patients at baseline, according to predicted FVC%

From: Clinical management and acute exacerbations in patients with idiopathic pulmonary fibrosis in Spain: results from the OASIS study

Management intervention

Total sample

N = 204

Predicted FVC% at baseline

FVC < 50%

N = 22

FVC 50–80%

N = 152

FVC > 80%

N = 30

p value

Patients receiving a pharmacological treatment associated with IPF, n (%)a

     

 Antifibroticb

166 (81.4%)

16 (72.7%)

129 (84.9%)

21 (70.0%)

0.0876

 Systemic corticosteroidsc

10 (4.9%)

4 (18.2%)

5 (3.3%)

1 (3.3%)

0.0320

 Antiacidsd

72 (35.3%)

7 (31.8%)

57 (37.5%)

8 (26.7%)

0.4921

 Antibiotics for systemic usee

6 (2.9%)

1 (4.5%)

4 (2.6%)

1 (3.3%)

0.6290

 Otherf

11 (5.4%)

2 (9.1%)

7 (4.6%)

2 (6.7%)

-

Patients receiving a non-pharmacological treatment associated with IPF, n (%)a

     

Total, n (%)

41 (20.1%)

14 (63.6%)

26 (17.1%)

1 (3.3%)

 < 0.0001

 Liquid oxygen therapy, n (%)

13 (6.4%)

5 (22.7%)

7 (4.6%)

1 (3.3%)

0.0142

 Electric portable oxygen therapy, n (%)

9 (4.4%)

2 (9.1%)

7 (4.6%)

0 (0.0%)

0.2849

 Oxygen therapy concentrator, n (%)

12 (5.9%)

6 (27.3%)

6 (3.9%)

0 (0.0%)

0.0007

 Oxygen therapy portable device, n (%)

6 (2.9%)

2 (9.1%)

3 (2.0%)

1 (3.3%)

0.1153

 Non-invasive mechanical ventilation, n (%)

3 (1.5%)

2 (9.1%)

1 (0.7%)

0 (0.0%)

0.0410

 High Flow Nasal Cannulas (HFNC), n (%)

0 (0.0%)

0 (0.0%)

0 (0.0%)

0 (0.0%)

–

 Flu and pneumococcal vaccination, n (%)

9 (4.4%)

4 (18.2%)

5 (3.3%)

0 (0.0%)

0.0153

 Nutritional supplements, n (%)

2 (1.0%)

2 (9.1%)

0 (0.0%)

0 (0.0%)

0.0112

 Other, n (%)

1 (0.5%)

1 (4.5%)

0 (0.0%)

0 (0.0%)

0.1078

Patients receiving help from a caregiver, n (%)

41 (20.1%)

9 (40.9%)

27 (17.8%)

5 (16.7%)

0.0356

 Formal, n (%‡)

2 (4.9%)

1 (11.1%)

0 (0.0%)

1 (20.0%)

0.1110

 Informal, n (%‡)

39 (95.1%)

8 (88.9%)

27 (100.0%)

4 (80.0%)

 
  1. In bold, p-values < 0.05
  2. FVC forced vital capacity, IPF idiopathic pulmonary fibrosis, SD standard deviation
  3. aEither to treat IPF or to treat some comorbidity or symptomatology associated with IPF. Did not include the treatments administered during a hospitalization
  4. bIncludes nintedanib (44.6% of all patients receiving antifibrotics [74/166]) and pirfenidone (55.4% [92/166])
  5. cIncludes methylprednisolone and prednisone
  6. dIncludes esomeprazole, lansoprazole, omeprazole, pantoprazole, rabeprazole and ranitidine
  7. eIncludes azithromycin and sulfamethoxazole plus trimethoprim
  8. fIncludes: anticoagulants (dabigatran etexilate), anti-HTAP (Phosphodiesterase-5 Blockers) (sildenafil), diuretics (furosemide), calcium. combinations with vitamin D and/or other drugs, immunosuppressants, alendronic acid, amlodipine, amphotericin B, calcifediol, calcium carbonate, folic acid, furosemide, indacaterol and glycopyrronium bromide, ipratropium bromide, tiotropium bromide, umeclidinium bromide, vilanterol and fluticasone furoate
  9. ‡Over total number of patients receiving help from a caregiver in the total sample (n=41) and in each FVC% predicted group
Back to article page

Respiratory Research

ISSN: 1465-993X

Contact us